Fertility is closely linked to metabolic health , with obesity being a significant factor that can negatively affect reproductive function in both males and females . Having overweight or obesity can contribute to hormonal imbalances , insulin resistance , chronic inflammation , and altered reproductive hormone signaling, all of which may impair fertility.
In females, obesity is often associated with conditions such as polyendocrine metabolic ovarian syndrome (PMOS) , formerly knows as PCOS, while in males, it can reduce testosterone levels and adversely affect sperm quality . Thus, lifestyle changes , such as adopting balanced dietary plans, engaging in regular physical activity, and maintaining a healthy weight, can help enhance reproductive outcomes and support fertility.
GLP-1 receptor agonists , such as Wegovy , which contain the active ingredient semaglutide , are a class of medications widely used for obesity and type 2 diabetes . Now, emerging research suggests these medications may also have positive effects on reproductive health.
Two studies indicate that GLP-1 drugs may offer reproductive benefits, in addition to supporting weight loss and metabolic health.
Medical News Today published a clinical update in Research Highlights on 18 Jun 2026.
The item focuses on GLP-1 drugs show early promise for improving fertility in males and females.
Review the original article for the full source wording and details.